By: Editorial Staff, The American Journal of Human Genetics (AJHG)
Breast cancer remains one of the most significant public health challenges of the 21st century. With one in eight women in the United States projected to receive a diagnosis in their lifetime, the disease is a pervasive presence in families and communities globally. While decades of research have identified high-penetrance genes such as BRCA1, BRCA2, and CHEK2, these known factors account for only a fraction of hereditary risk. A significant "missing heritability" persists, leaving many families without clear answers regarding their genetic susceptibility.
In a recent breakthrough published in The American Journal of Human Genetics (AJHG), Dr. Jennifer Asmussen and her colleagues have unveiled a powerful new approach to identifying early-onset breast cancer risk genes. By leveraging the immense scale of modern biobanks and innovative computational algorithms, the study, titled "Ultra-rare functional variants reveal early-onset breast cancer risk genes and pathways in the UK Biobank and All of Us Research program," marks a significant pivot toward precision medicine.
The Core Investigation: Bridging the Knowledge Gap
At the heart of Dr. Asmussen’s work lies a fundamental question: Why do so many women with a strong family history of breast cancer test negative for the most common, well-studied mutations? The answer, as the research suggests, may lie in the "dark matter" of our genome—ultra-rare functional variants that are difficult to detect using standard population-level analysis.
The Power of Biobanks
Historically, genome-wide association studies (GWAS) have focused on common variants—genetic markers found in a large percentage of the population. While these studies have been successful in identifying common risk loci, they often provide only a small piece of the puzzle. Dr. Asmussen’s research takes a different path, utilizing the UK Biobank and the All of Us Research Program. These initiatives represent a paradigm shift in medical research, combining massive exome and genome sequencing data with longitudinal electronic health records.
By analyzing these datasets, the research team was able to move beyond common markers to isolate rare, high-impact mutations that carry a much stronger influence on individual disease risk.
Chronology of the Project
The journey to this discovery was neither linear nor simple. Dr. Asmussen’s career path serves as a testament to the multidisciplinary nature of modern genetics.
- Foundation Phase: The project began with the identification of a significant gap in clinical risk assessment. Dr. Asmussen recognized that existing diagnostic pipelines were failing to account for the complex, polygenic nature of breast cancer in many high-risk families.
- Methodological Development: Working within the Lichtarge Lab, the team turned their attention to the "Evolutionary Action" (EA) framework. This computational method identifies genes and pathways that are enriched for mutations deemed functionally impactful by evolutionary conservation metrics.
- Data Integration: The team integrated vast datasets from the UK Biobank and the All of Us program. This phase involved rigorous data cleaning and the application of the EA-Pathways algorithm to sift through thousands of rare genetic variants.
- Validation and Publication: Following the computational identification of candidate genes, the research entered a validation phase, leading to the recent publication in AJHG. The project now shifts toward collaborating with experimental biologists to confirm these findings in the lab.
Supporting Data and Technical Innovation
The technical backbone of this study is the EA-Pathways algorithm. Unlike traditional methods that require large, matched control groups—which are often contaminated by "cases-in-waiting" who may develop the disease later in life—EA-Pathways relies on the statistical properties of the Evolutionary Action variant impact score.
Why Evolutionary Action?
Evolutionary conservation is a proxy for biological importance. If a specific region of a protein is conserved across millions of years of evolution, a mutation in that region is likely to be detrimental to the protein’s function. By scoring variants based on their evolutionary significance, the algorithm can prioritize mutations that are most likely to drive cancer, even if those mutations are found in only a handful of individuals.
The Role of Diverse Populations
One of the most critical aspects of the research is its commitment to inclusivity. By utilizing the All of Us Research Program, which prioritizes the participation of underrepresented communities in biomedical research, the team is working toward a more equitable understanding of cancer risk. This is essential, as genetic risk factors can vary significantly across different ancestral backgrounds.
Perspectives from the Researcher
In an exclusive interview with AJHG, Dr. Jennifer Asmussen, a Faculty Instructor in the Department of Molecular and Human Genetics at Baylor College of Medicine, reflected on the motivations and implications of her work.
"Every analysis is meaningful," Dr. Asmussen noted when asked about the excitement of the discovery process. "Even if I have run an algorithm 100 times, maybe I am only changing a single hyperparameter or tweaking the composition of a cohort, I am always eager to analyze the output. It never gets old."
She emphasized that her work is not merely an academic exercise; it is driven by the human reality of the disease. "Breast cancer is a prevalent female cancer… We all know someone affected by breast cancer and have witnessed how a diagnosis impacts their lives. Addressing this knowledge gap could improve risk assessment for thousands of women."
A Non-Linear Career Path
Dr. Asmussen’s career is a roadmap for aspiring scientists. She transitioned from a bench scientist to a university program administrator, then to a postdoctoral fellow, and finally to a computational biologist. She credits her time managing undergraduate research programming at the University of Houston for developing the communication and management skills necessary to lead large-scale research projects.
"My advice to other trainees and future scientists is to follow your heart, trust your instinct, don’t be afraid to take the road less traveled, and never stop learning or expanding your knowledge base," she advised.
Broader Implications for the Genetics Community
The publication of this research has significant implications for the wider medical and scientific community.
1. Broad Applicability
The EA-Pathways algorithm is not limited to breast cancer. It is a robust tool that can be applied to virtually any complex disease, including neurodegenerative conditions, metabolic disorders, and other cancers. Its ability to bypass the need for traditional, often flawed, control groups makes it an invaluable asset in the era of Big Data.
2. Refining Risk Stratification
By identifying novel, high-to-moderate impact genes, this work allows clinicians to provide more accurate genetic counseling. Families who were previously told they had "no identifiable risk" may soon have access to new screening panels that account for these ultra-rare variants.
3. A Call for Continued Collaboration
The study underscores the necessity of collaboration between computational biologists and experimental researchers. As Dr. Asmussen notes, the short-term goal is to validate these findings in the lab, a process that requires the synergy of genomic insights and molecular biology.
Conclusion: The Path Forward
The work of Dr. Asmussen and her team represents a significant step toward the "Holy Grail" of modern genetics: a complete, actionable map of human disease risk. By combining the vast, altruistic contributions of biobank participants with the precision of evolutionary biology, the research provides a new lens through which we can view hereditary cancer.
As we look to the future, the integration of these findings into clinical practice will be the next major hurdle. However, the methodology established here—characterized by its scalability, inclusivity, and technical rigor—offers a clear roadmap.
For Dr. Asmussen, the mission continues both inside and outside the lab. Whether she is analyzing cohorts or experimenting with new recipes in her kitchen—a hobby she describes as a parallel to her scientific process—her focus remains on the transformative power of discovery. Through her work, the future of breast cancer prevention looks not only more informed but significantly more personalized, offering hope to families across the globe.
For more information on the research, read the full paper in the latest issue of The American Journal of Human Genetics.
About the Author
